TRAVERE THERAPEUTICS INC
NASDAQ: TVTX (Travere Therapeutics, Inc.)
Last update: 21 hours ago34.69
-0.04 (-0.12%)
| Previous Close | 34.73 |
| Open | 34.70 |
| Volume | 1,596,475 |
| Avg. Volume (3M) | 2,255,988 |
| Market Cap | 3,103,794,944 |
| Price / Earnings (Forward) | 27.55 |
| Price / Sales | 7.11 |
| Price / Book | 43.09 |
| 52 Weeks Range | |
| Earnings Date | 30 Oct 2025 |
| Profit Margin | -82.88% |
| Operating Margin (TTM) | -52.21% |
| Diluted EPS (TTM) | -2.78 |
| Quarterly Revenue Growth (YOY) | 97.50% |
| Total Debt/Equity (MRQ) | 1,220.07% |
| Current Ratio (MRQ) | 2.05 |
| Operating Cash Flow (TTM) | -160.66 M |
| Levered Free Cash Flow (TTM) | -239.23 M |
| Return on Assets (TTM) | -23.21% |
| Return on Equity (TTM) | -422.66% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Travere Therapeutics, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -3.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 4.0 |
| Average | 1.25 |
|
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) - rare kidney disorders that often cause end-stage kidney disease. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 0.75% |
| % Held by Institutions | 113.30% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 47.00 (HC Wainwright & Co., 35.49%) | Buy |
| Median | 35.00 (0.89%) | |
| Low | 25.00 (Stifel, -27.93%) | Hold |
| Average | 36.40 (4.93%) | |
| Total | 3 Buy, 2 Hold | |
| Avg. Price @ Call | 28.52 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Piper Sandler | 04 Nov 2025 | 35.00 (0.89%) | Hold | 34.13 |
| TD Cowen | 31 Oct 2025 | 40.00 (15.31%) | Buy | 35.16 |
| HC Wainwright & Co. | 19 Sep 2025 | 47.00 (35.49%) | Buy | 24.85 |
| 10 Sep 2025 | 47.00 (35.49%) | Buy | 27.31 | |
| Stifel | 12 Sep 2025 | 25.00 (-27.93%) | Hold | 23.47 |
| Wells Fargo | 11 Sep 2025 | 35.00 (0.89%) | Buy | 25.00 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |